Incannex – APIRx Pharmaceuticals Acquisition May 2022

The acquisition of APIRx delivers a strong portfolio
of patented drug candidates, with 22 development
programs covering a total addressable market of
US$400B per annum.
Together, Incannex and APIRx will form the world’s
largest portfolio of patented medicinal cannabinoid
drug formulations and psychedelic treatment protocols.
The APIRx takeover is anticipated to be seamless, as
the development of assets is congruent with current
operational capabilities and our pharmaceutical
development strategy targeting FDA registration.